AI Analysis
Log in to generate an AI summary for this stock.
Log in to generate a MOAT report for this stock.
Log in to generate an earnings report for this stock.
Log in to generate an operating leverage report for this stock.
Log in to generate a management report for this stock.
Log in to generate a valuation report for this stock.
Adagene Inc.
Video analysis: ADAG
All videosNo video analysis for this stock yet. Request one from our team.
News: ADAG
Adagene Announces that Third Arc Bio Has Selected First Lead Candidate under Amended Strategic Collaboration for Development of Masked CD3 T Cell Engagers Utilizing SAFEbody® Technology
Amended terms of agreement include a transition to an integrated asset and technology partnership. SAN DIEGO and SUZHOU, China, Sept.
Adagene Achieves Milestone in Collaboration with Exelixis for Advancement of SAFEbody® Antibody-Drug Conjugate Candidates
SAN DIEGO and SUZHOU, China, Sept. 09, 2026 (GLOBE NEWSWIRE) -- Adagene Inc. (“Adagene”) (Nasdaq: ADAG), a platform-driven, clinical-stage biotechnology company transforming the discovery and development of novel antibody-based therapies, today announced the achievement of a milestone in its ongoing collaboration and license agreement with Exelixis, Inc. (“Exelixis”).
Adagene to Participate in Three Upcoming Investor Conferences
SAN DIEGO and SUZHOU, China, Aug. 20, 2026 (GLOBE NEWSWIRE) -- Adagene Inc. (Nasdaq: ADAG) a platform-driven, clinical-stage biotechnology company transforming the discovery and development of novel antibody-based therapies, today announced that senior management will participate in three upcoming investor conferences taking place in New York, New York. 2026 Cantor Global Healthcare Conference; New York, NY – September 9-11, 2026 Format: 1x1 Meetings Date/Time: September 11, 2026 Morgan Stanley 24th Annual Global Healthcare Conference; New York, NY – September 14-16, 2026 Format: Fireside Chat and 1x1 Meetings Fireside Chat Date/Time: September 15, 2026, 10:45–11:20 AM (Eastern Time) H.C.
Adagene Reports Six Months 2026 Financial Results and Provides Corporate Updates
Randomized Phase 2 trial in microsatellite stable colorectal cancer (MSS CRC) ongoing, with results expected in 1H 2027; potential registration trial expected in 2027 once recommended dose regimen has been established
